{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:05:43Z","timestamp":1780567543522,"version":"3.54.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1007\/bf02938621","type":"journal-article","created":{"date-parts":[[2008,8,19]],"date-time":"2008-08-19T02:39:45Z","timestamp":1219113585000},"page":"38-43","source":"Crossref","is-referenced-by-count":23,"title":["Monitoring osteoporosis therapies"],"prefix":"10.1007","volume":"5","author":[{"given":"Paul D.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF02938621_CR1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00198-004-1773-4","volume":"16","author":"R Lindsay","year":"2005","unstructured":"Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH:Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.Osteoporos Int 2005,16:372\u2013379.","journal-title":"Osteoporos Int"},{"key":"BF02938621_CR2","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1056\/NEJM199709043371003","volume":"337","author":"B Dawson-Hughes","year":"1997","unstructured":"Dawson-Hughes B, Harris SS, Krall EA, Dallal GE:Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older.N Engl J Med 1997,337:670\u2013676.","journal-title":"N Engl J Med"},{"key":"BF02938621_CR3","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1001\/jama.293.18.2257","volume":"293","author":"HA Bischoff-Ferrari","year":"2005","unstructured":"Bischoff-Ferrari HA, Willett WC, Wong JB, et al.:Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials.JAMA 2005,293:2257\u20132264.","journal-title":"JAMA"},{"key":"BF02938621_CR4","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, et al.:Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.Lancet 1996,348:1535\u20131541.","journal-title":"Lancet"},{"key":"BF02938621_CR5","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, et al.:Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.JAMA 1999,282:1344\u20131352.","journal-title":"JAMA"},{"key":"BF02938621_CR6","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut","year":"2004","unstructured":"Chesnut CH III, Skag A, Christiansen C, et al.:Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.J Bone Miner Res 2004,19:1241\u20131249.","journal-title":"J Bone Miner Res"},{"key":"BF02938621_CR7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","volume":"102","author":"CH Chesnut","year":"2000","unstructured":"Chesnut CH III, Silverman S, Andriano K, et al.:A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group.Am J Med 2000,102:267\u2013276.","journal-title":"Am J Med"},{"key":"BF02938621_CR8","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, et al.:Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis.N Engl J Med 2001,344:1434\u20131441.","journal-title":"N Engl J Med"},{"key":"BF02938621_CR9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0002-9343(03)00362-0","volume":"115","author":"AN Tosteson","year":"2003","unstructured":"Tosteson AN, Grove MR, Hammond CS, et al.:Early discontinuation of treatment for osteoporosis.Am J Med 2003,115:209\u2013216.","journal-title":"Am J Med"},{"key":"BF02938621_CR10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0002-9343(97)00467-1","volume":"102","author":"NH Miller","year":"1997","unstructured":"Miller NH:Compliance with treatment regimens in chronic asymptomatic diseases.Am J Med 1997,102:43\u201349.","journal-title":"Am J Med"},{"key":"BF02938621_CR11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1185\/030079905X41390","volume":"21","author":"PD Miller","year":"2005","unstructured":"Miller PD, Hochberg MC, Wehren LE, et al.:How useful are measures of BMD and bone turnover? Curr Med Res Opin 2005,21:545\u2013553.","journal-title":"Curr Med Res Opin"},{"key":"BF02938621_CR12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11914-005-0018-6","volume":"3","author":"PD Miller","year":"2005","unstructured":"Of importance Miller PD:Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction.Curr Osteoporos Rep 2005,3:103\u2013110. This is a recent review of the value of surrogate markers of bone turnover and how they can be used in clinical practice to asses efficacy of osteoporosis therapy.","journal-title":"Curr Osteoporos Rep"},{"issue":"4 Suppl 1","key":"BF02938621_CR13","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.amjmed.2005.12.020","volume":"119","author":"SL Bonnick","year":"2006","unstructured":"Bonnick SL, Shulman L:Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 2006,119(4 Suppl 1):S25-S31.","journal-title":"Am J Med"},{"key":"BF02938621_CR14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1385\/JCD:6:4:307","volume":"6","author":"EM Lewiecki","year":"2003","unstructured":"Lewiecki EM:Nonresponders to osteoporosis therapy.J Clin Densitom 2003,6:307\u2013314.","journal-title":"J Clin Densitom"},{"key":"BF02938621_CR15","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","volume":"15","author":"JJ Caro","year":"2004","unstructured":"Caro JJ, Isaac KJ, Huybrechts KF, et al.:The impact of compliance with osteoporosis therapy on fracture rates in actual practice.Osteoporos Int 2004,15:1003\u20131008.","journal-title":"Osteoporos Int"},{"key":"BF02938621_CR16","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"E Siris","year":"2006","unstructured":"Of major importance Siris E, Harris ST, Rosen CJ, et al.:Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.Mayo Clin Proc 2006,81:1013\u20131022. This is a review of two large US databases showing the relationship between adherence to osteoporosis therapy and the rate of atraumatic fracture.","journal-title":"Mayo Clin Proc"},{"key":"BF02938621_CR17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jocd.2006.09.002","volume":"9","author":"P Cram","year":"2006","unstructured":"Cram P, Schlechte J, Christensen A:A randomized trial to assess the impact of direct reporting of DXA scan results to patients on quality of osteoporosis care.J Clin Densitom 2006,9:393\u2013398.","journal-title":"J Clin Densitom"},{"key":"BF02938621_CR18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s001980070097","volume":"11","author":"R Dowd","year":"2000","unstructured":"Dowd R, Recker RR, Heaney RP:Study subjects and ordinary patients.Osteoporos Int 2000,11:533\u2013536.","journal-title":"Osteoporos Int"},{"key":"BF02938621_CR19","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1385\/JCD:5:3S:S01","volume":"5","author":"L Lenchik","year":"2002","unstructured":"Lenchik L, Leib ES, Hamdy RC, et al.; International Society for Clinical Densitometry Position Development Panel and Scientific Advisory Committee:Executive summary International Society for Clinical Densitometry Position Development Conference Denver, Colorado, July 20\u201322, 2001.J Clin Densitom 2002,5(suppl):S1-S3.","journal-title":"J Clin Densitom"},{"key":"BF02938621_CR20","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1210\/jcem.86.8.9997","volume":"86","author":"SR Cummings","year":"2001","unstructured":"Cummings SR, Parfitt AM:Bone density regression to the mean and the individual patient.J Clin Endocrinol Metab 2001,86:4001\u20134002.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF02938621_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1385\/JCD:4:1:01","volume":"4","author":"L Lenchik","year":"2001","unstructured":"Lenchik L, Watts NB:Regression to the mean: what does it mean? Using bone density results to monitor treatment of osteoporosis.J Clin Densitom 2001,4:1\u20134.","journal-title":"J Clin Densitom"},{"key":"BF02938621_CR22","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s00198-004-1770-7","volume":"16","author":"RD Chapurlat","year":"2005","unstructured":"Chapurlat RD, Palmero L, Ramsay P, Cummings SR:Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial.Osteoporos Int 2005,16:842\u2013848.","journal-title":"Osteoporos Int"},{"key":"BF02938621_CR23","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1359\/JBMR.050814","volume":"20","author":"NB Watts","year":"2005","unstructured":"Watts NB, Guesens P, Barton IP, Felsenberg D:Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.J Bone Miner Res 2005,20:2097\u20132104.","journal-title":"J Bone Miner Res"},{"key":"BF02938621_CR24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","volume":"85","author":"RD Wasnich","year":"2000","unstructured":"Wasnich RD, Miller PD:Antifracture efficacy of antiresorptive agents are [sic] related to changes in bone density.J Clin Endocrinol Metab 2000,85:231\u2013236.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF02938621_CR25","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","volume":"112","author":"SR Cummings","year":"2002","unstructured":"Cummings SR, Karpf DB, Harris F, et al.:Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with anti-resorptive drugs.Am J Med 2002,112:281\u2013289.","journal-title":"Am J Med"},{"key":"BF02938621_CR26","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","volume":"87","author":"MC Hochberg","year":"2002","unstructured":"Hochberg MC, Greenspan SL, Wasnich RD, et al.:Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatment with antiresorptive agents.J Clin Endocrinol Metab 2002,87:1586\u20131592.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF02938621_CR27","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1359\/jbmr.060802","volume":"21","author":"P Chen","year":"2006","unstructured":"Of major importance Chen P, Miller PD, Delmas PD, et al.:Change in lumbar spine bone mineral density and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.J Bone Miner Res 2006,21:1785\u20131790. Description of a new statistical method to examine the relationship between changes in bone mineral density and the reduction of fracture risk with teriparatide therapy.","journal-title":"J Bone Miner Res"},{"key":"BF02938621_CR28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1385\/JCD:8:2:143","volume":"8","author":"EM Lewiecki","year":"2005","unstructured":"Lewiecki EM, Miller PD, Leib ES, Bilezikian JP:Response to \u201cThe Perspective of the International Osteoporosis Foundation on the Official Positions of the International Society for Clinical Densitometry,\u201d by John A Kanis et al. [comment].J Clin Densitom 2005,8:143\u2013144.","journal-title":"J Clin Densitom"},{"key":"BF02938621_CR29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1385\/JCD:4:2:105","volume":"4","author":"SL Bonnick","year":"2001","unstructured":"Bonnick SL, Johnston CC Jr, Kleerekoper M, et al.:Importance of precision in bone density measurements.J Clin Densitom 2001,4:105\u2013110.","journal-title":"J Clin Densitom"},{"issue":"S6","key":"BF02938621_CR30","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/s001980070002","volume":"11","author":"PD Delmas","year":"2000","unstructured":"Delmas PD, Eastell R, Garnero P, et al. for the Committee of Scientific Advisors of the International Osteoporosis Foundation:A position paper on the use of biochemical markers of bone turnover in osteoporosis.Osteoporosis Int 2000,11(S6):S2-S17.","journal-title":"Osteoporosis Int"},{"key":"BF02938621_CR31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1385\/JCD:2:3:323","volume":"2","author":"PD Miller","year":"1999","unstructured":"Miller PD, Baran DT, Bilezikian JP, et al.:Practical clinical application of biochemical markers of bone turnover.J Clin Densitom 1999,2:323\u2013342.","journal-title":"J Clin Densitom"},{"key":"BF02938621_CR32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S8756-3282(00)00270-2","volume":"26","author":"BL Riggs","year":"2000","unstructured":"Riggs BL:Are biochemical markers for bone turnover clinically useful for monitoring therapy in individual osteoporotic patients? [editorial].Bone 2000,26:551\u2013552.","journal-title":"Bone"},{"key":"BF02938621_CR33","first-page":"50","volume":"4","author":"P Garnero","year":"2004","unstructured":"Garnero P, Delmas PD:Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women [review].J Musculoskelet Neuronal Interact 2004,4:50\u201363.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"BF02938621_CR34","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","volume":"18","author":"R Eastell","year":"2003","unstructured":"Eastell R, Barton I, Hannon RA, et al.:Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.J Bone Miner Res 2003,18:1051\u20131056.","journal-title":"J Bone Miner Res"},{"key":"BF02938621_CR35","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","volume":"19","author":"DC Bauer","year":"2004","unstructured":"Bauer DC, Black DM, Garnero P, et al.:Change in bone turnover and hip, non-spine and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial.J Bone Miner Res 2004,19:1250\u20131258.","journal-title":"J Bone Miner Res"},{"key":"BF02938621_CR36","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1210\/jc.2004-1091","volume":"90","author":"SL Greenspan","year":"2005","unstructured":"Greenspan SL, Resnick NM, Parker RA:Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.J Clin Endocrinol Metab 2005,90:2762\u20132767.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF02938621_CR37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00198-006-0218-7","volume":"18","author":"JT Schousboe","year":"2007","unstructured":"Schousboe JT, Bauer DC, Nyman JA, et al.:Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy.Osteoporos Int 2007,18:201\u2013210.","journal-title":"Osteoporos Int"},{"key":"BF02938621_CR38","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1359\/JBMR.051018","volume":"21","author":"DC Bauer","year":"2006","unstructured":"Bauer DC, Garnero P, Hochberg MC, et al. for the Intervention Research Group:Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the Fracture Intervention Trial.J Bone Miner Res 2006,21:292\u2013299.","journal-title":"J Bone Miner Res"},{"key":"BF02938621_CR39","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","volume":"34","author":"R Recker","year":"2004","unstructured":"Recker R, Stakkestad JA, Chesnut CH 3rd, et al.:Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.Bone 2004,34:890\u2013899.","journal-title":"Bone"},{"key":"BF02938621_CR40","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00223-004-0039-7","volume":"75","author":"LG Ste-Marie","year":"2004","unstructured":"Ste-Marie LG, Sod E, Johnson T, Chines A:Five years treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.Calcif Tissue Int 2004,75:469\u2013476.","journal-title":"Calcif Tissue Int"},{"key":"BF02938621_CR41","first-page":"398","volume":"M358","author":"RR Recker","year":"2005","unstructured":"Recker RR:Alendronate effects on histomorphometric parameters: is there evidence for over-suppression of bone turnover? [abstract].J Bone Miner Res 2005,M358:S398.","journal-title":"J Bone Miner Res"},{"key":"BF02938621_CR42","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4158\/EP.10.2.139","volume":"10","author":"PD Miller","year":"2004","unstructured":"Miller PD, Bilezikian JP, Deal C, et al.:Clinical use of teriparatide in the real world: initial insights.Endocr Pract 2004,10:139\u2013148.","journal-title":"Endocr Pract"},{"key":"BF02938621_CR43","first-page":"2004","volume":"10","author":"AB Hodsman","year":"2005","unstructured":"Hodsman AB, Bauer DC, Dempster D, et al.:Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.Endocr Rev 2005,10:2004\u20132006.","journal-title":"Endocr Rev"},{"key":"BF02938621_CR44","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1359\/jbmr.2003.18.3.539","volume":"18","author":"JR Zanchetta","year":"2003","unstructured":"Zanchetta JR, Bogado CE, Ferretti JL, et al.:Effects of teriparatide [recombinant human parathyroid hormone (1\u201334)] on cortical bone in postmenopausal women with osteoporosis.J Bone Miner Res 2003,18:539\u2013543.","journal-title":"J Bone Miner Res"},{"key":"BF02938621_CR45","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.bone.2005.03.003","volume":"36","author":"K Uusi-Rasi","year":"2005","unstructured":"Uusi-Rasi K, Semanick LM, Zanchetta JR, et al.:Effects of teriparatide [rhPTH (1\u201334)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.Bone 2005,36:948\u2013958.","journal-title":"Bone"},{"key":"BF02938621_CR46","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","volume":"20","author":"P Chen","year":"2005","unstructured":"Chen P, Satterwhite JH, Licata AA, et al.:Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.J Bone Miner Res 2005,20:962\u2013970.","journal-title":"J Bone Miner Res"},{"key":"BF02938621_CR47","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1210\/jc.2003-1703","volume":"90","author":"H Dobnig","year":"2005","unstructured":"Dobnig H, Sipos A, Jiang Y, et al.:Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy.J Clin Endocrinol Metab 2005,90:3970\u20133977.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF02938621_CR48","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1210\/jc.2006-1178","volume":"91","author":"EM Lewiecki","year":"2006","unstructured":"Of major importance Lewiecki EM, Laster A:Clinical review: clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry.J Clin Endocrinol Metab 2006,91:4215\u20134222. A thorough review of the science and clinical application of vertebral fracture assessment by DXA for the identification of vertebral fractures.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF02938621_CR49","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","volume":"285","author":"R Lindsay","year":"2001","unstructured":"Lindsay R, Silverman SL, Cooper C, et al.:Risk of new vertebral fracture in the year following a fracture.JAMA 2001,285:320\u2013323.","journal-title":"JAMA"},{"key":"BF02938621_CR50","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1210\/jc.2004-0826","volume":"90","author":"JC Gallagher","year":"2005","unstructured":"Gallagher JC, Genant HK, Crans GG, et al.:Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures.J Clin Endocrinol Metab 2005,90:1583\u20131587.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF02938621_CR51","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S8756-3282(03)00241-2","volume":"33","author":"P Delmas","year":"2003","unstructured":"Delmas P, Genant HK, Crans GG, et al.:Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.Bone 2003,33:522\u2013532.","journal-title":"Bone"},{"key":"BF02938621_CR52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jocd.2006.05.006","volume":"9","author":"T Vokes","year":"2006","unstructured":"Vokes T, Bachman D, Baim S, et al.; International Society for Clinical Densitometry:Vertebral fracture assessment: the 2005 ISCD Official Positions.J Clin Densitom 2006,9:37\u201346.","journal-title":"J Clin Densitom"},{"key":"BF02938621_CR53","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jocd.2006.07.002","volume":"9","author":"EM Lewiecki","year":"2006","unstructured":"Of major importance Lewiecki EM, Binkley N, Petak SM:DXA quality matters.J Clin Densitom 2006,9:388\u2013392. A landmark study showing that quality control and proper interpretation are vital to the clinical implementation of DXA scans.","journal-title":"J Clin Densitom"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02938621.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02938621\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02938621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T22:58:40Z","timestamp":1558565920000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02938621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["BF02938621"],"URL":"https:\/\/doi.org\/10.1007\/bf02938621","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}